1. Home
  2. ECOR vs SPRO Comparison

ECOR vs SPRO Comparison

Compare ECOR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo electroCore Inc.

ECOR

electroCore Inc.

N/A

Current Price

$9.50

Market Cap

85.6M

Sector

Health Care

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECOR
SPRO
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.6M
71.6M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
ECOR
SPRO
Price
$9.50
$1.21
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
95.4K
478.5K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
$32,032,000.00
$66,802,000.00
Revenue This Year
$33.60
N/A
Revenue Next Year
$30.40
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
27.20
39.24
52 Week Low
$4.41
$1.08
52 Week High
$10.95
$3.08

Technical Indicators

Market Signals
Indicator
ECOR
SPRO
Relative Strength Index (RSI) 56.76 39.88
Support Level $5.70 $1.18
Resistance Level $10.60 $1.29
Average True Range (ATR) 0.80 0.04
MACD -0.14 0.03
Stochastic Oscillator 43.30 52.63

Price Performance

Historical Comparison
ECOR
SPRO

About ECOR electroCore Inc.

electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: